Rituximab + Azathioprine
Phase 3Completed 0 watching 0 views this week📈 Rising
77
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
Conditions
Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Microscopic Polyangiitis, Wegener Granulomatosis
Trial Timeline
Apr 1, 2013 → Nov 21, 2019
NCT ID
NCT01697267About Rituximab + Azathioprine
Rituximab + Azathioprine is a phase 3 stage product being developed by Roche for Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis. The current trial status is completed. This product is registered under clinical trial identifier NCT01697267. Target conditions include Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis, Microscopic Polyangiitis, Wegener Granulomatosis.
Hype Score Breakdown
Clinical
27
Activity
18
Company
10
Novelty
9
Community
10
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01697267 | Phase 3 | Completed |
Competing Products
5 competing products in Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Iptacopan + Placebo + Rituximab | Novartis | Phase 2 | 52 |
| CCX168 | Amgen | Phase 1 | 32 |
| CCX168 + Midazolam + Celecoxib + Itraconazole + Rifampicin | Amgen | Phase 1 | 32 |
| CCX168 + Placebo | Amgen | Phase 1 | 32 |
| [14C]CCX168 | Amgen | Phase 1 | 32 |